title: Serum levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors.
abstract: To determine the usefulness of serum KL-6 levels for predicting the occurrence of radiation pneumonitis (RP) after the application of single high-dose stereotactic radiation therapy for lung tumors, the serum KL-6 levels were measured in 16 patients before irradiation and every 1 or 2 months thereafter. Three of the 16 patients experienced RP of grade 3 severity according to the European Organization for Research and Treatment of Cancer/Radiation Therapy Oncology Group toxicity criteria. RP occurred 3 months after the completion of radiation therapy in two patients, and 4 months after completion in one patient. RP occurred at significantly increased frequencies in patients with primary lung cancer (p = 0.01) and adenocarcinoma (p = 0.01), and in those undergoing the concurrent irinotecan therapy (p = 0.02). In all 16 patients, the lactate dehydrogenase level remained normal during the follow-up period. In all three of the patients with RP, KL-6 levels increased by > 1.5-fold compared to the pretreatment value and over the cutoff level of 500 IU. The ratio of the increase in serum KL-6 values 2 months after the patient had undergone irradiation showed a significant correlation with the occurrence of RP (p = 0.04). In conclusion, KL-6 is a useful marker for prediction of the occurrence of RP after single, fractional, high-dose stereotactic irradiation of lung tumors.
authors.affiliation: Department of Radiation Therapy and Oncology, International Medical Center of Japan, Tokyo, Japan.
authors.forename: Ryusuke
authors.initials: R
authors.lastname: Hara
authors.forename: Jun
authors.initials: J
authors.lastname: Itami
authors.forename: Takafumi
authors.initials: T
authors.lastname: Komiyama
authors.forename: Daiki
authors.initials: D
authors.lastname: Katoh
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Kondo
mesh_terms: D000230:Adenocarcinoma / Q000532:radiotherapy; D000368:Aged; D000369:Aged, 80 and over; D000941:Antigens / Q000097:blood*; D000951:Antigens, Neoplasm; D015415:Biomarkers / Q000097:blood; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy; D005260:Female; D006023:Glycoproteins / Q000097:blood*; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008175:Lung Neoplasms / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D018396:Mucin-1; D009077:Mucins; D017564:Radiation Pneumonitis / Q000175:diagnosis* / Q000209:etiology; D011879:Radiotherapy Dosage; D013238:Stereotaxic Techniques
chemical_list: D000941:Antigens; D000951:Antigens, Neoplasm; D015415:Biomarkers; D006023:Glycoproteins; C060192:MUC1 protein, human; D018396:Mucin-1; D009077:Mucins; D007770:L-Lactate Dehydrogenase